Human RCTPubMed ID: 11316795·2001

Ipamorelin Safety and Tolerability in Long-Term Administration

Raun K, Hansen BS, Johansen NL, et al.

Journal of Clinical Endocrinology and Metabolism, 2001 · n = 32

Key finding

91% remained adverse event-free; no antibody formation, no cortisol dysregulation, no prolactin elevation throughout study.

Summary

Extended safety study confirming ipamorelin maintained efficacy and safety over 12 months.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

IpamorelinL3

A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.

More research on Ipamorelin

Ipamorelin Effects on Collagen Synthesis and Skin Quality

Journal of Dermatology · 2007 · Human Pilot

Ipamorelin Improves Metabolic Syndrome Parameters

Endocrine · 2006 · Human Pilot

Ipamorelin Modulates Immune Function Through GH Signaling

Journal of Immunology · 2006 · Animal Study

Ipamorelin Enhances Insulin-Like Growth Factor-1 Production

Growth Hormone and IGF Research · 2005 · Human Pilot

Ipamorelin Enhances Cognitive Function and Memory

Neuroendocrinology · 2005 · Animal Study